The evidence of the preceding chapters was generated largely in younger, fitter patients, and applying it unthinkingly to the frail elderly can harm. For an eighty-five-year-old with multiple conditions and limited life expectancy, the intensive blood-pressure target, the tight glycaemic control, and the stacked pillars that help a fifty-year-old may deliver little benefit — because the benefit takes years to arrive and the burden is immediate. This chapter is about matching the intensity of CKD care to the patient's prognosis and priorities, and about recognising that, often, less is more.
Reading the older kidney
The first task is interpretive. A reduced GFR is common with age, and much of it represents a low-risk ageing kidney rather than progressive disease destined for failure. Distinguishing the two uses the tools of Chapter 1: albuminuria, the trajectory of the GFR over time, and the kidney-failure risk equation, which together separate the stable, low-risk older patient who needs only monitoring from the genuinely progressive one. Over-labelling a stable reduced GFR as 'stage 3 CKD' and over-treating it is a common error in the very old. A second interpretive trap is sarcopenia: the frail elderly have little muscle, so they produce little creatinine, and a creatinine-based eGFR can flatter their kidney function — the reading looks better than the truth. Where the estimate matters, cystatin C or a combined equation, which is less muscle-dependent, gives a truer picture.
Competing risk and time-to-benefit
The decisive concept in frailty is competing risk. A frail older patient faces a high probability of dying from something other than their kidney, and the interventions this volume champions — slowing progression, reducing cardiovascular events — take years to pay off. If a treatment's time-to-benefit is several years and the patient's life expectancy is shorter, the treatment cannot help them and only burdens them. This is not ageism; it is arithmetic. The same logic that makes aggressive CKD therapy obviously right in a fifty-year-old makes it questionable in a frail ninety-year-old, and the variable that matters is not the birthday but the frailty: a fit older person may benefit like a younger one, while a frail one may not. Frailty assessment, therefore, drives the decisions more than chronological age.
Relaxing the targets
Several specific targets are relaxed in the frail. The intensive blood-pressure target of SPRINT was derived in a population that excluded the frail and nursing-home residents, and pushing blood pressure low in the frail causes orthostatic hypotension, falls, and AKI — harms that can outweigh the cardiovascular gain, so the target is individualised and usually relaxed. Glycaemic targets are loosened too, because hypoglycaemia, already more dangerous in CKD, is especially hazardous in the frail elderly with their falls and cognitive vulnerability, so a tight HbA1c is abandoned in favour of a safer, looser one. The pillars themselves remain valuable — an SGLT2 inhibitor or RAAS blockade can still help a fit older patient — but they are weighed against burden and time-to-benefit and against side effects such as volume depletion and falls, rather than reflexively maximised. The principle is individualisation, with the default leaning toward less intensity as frailty increases.
Deprescribing
If relaxing targets is the defensive move, deprescribing is the active one. The frail elderly accumulate long medication lists over years, and many of those drugs were started for benefits that take longer to materialise than the patient now has, or that now carry more burden than gain. Deprescribing is the systematic review and withdrawal of such drugs: a tight glycaemic agent whose harm now exceeds its benefit, a drug contributing to hypotension and falls, a preventive medication whose time-to-benefit exceeds the patient's prognosis. Done well, deprescribing reduces the pill burden, the side effects, the falls, and the cost, and it is a positive intervention, not a giving-up. The skill is to identify, for each drug, whether its benefit will arrive within the patient's likely lifespan and whether its burden is justified — and to stop it when the answer is no.
What remains effective care
Relaxing intensity is not the same as withdrawing care, and it is important to be clear about what remains effective and owed regardless of frailty. Nephrotoxin avoidance still matters — an avoidable insult harms the frail kidney as much as any. Reversible factors are still treated, symptoms are still controlled, falls are still prevented, and the patient is still given an honest prognosis and never abandoned. These are not the preference-sensitive intensity decisions; they are the baseline of good care that does not become optional because a patient is old or frail. Keeping this distinction clear — between the values-driven intensity choices and the effective care owed to everyone — prevents the slide from appropriate de-intensification into neglect.
Dialysis or conservative management?
For the frail older patient whose CKD does progress toward failure, the largest decision — whether to pursue dialysis or conservative kidney management — is preference-sensitive, and conservative management is often appropriate. As the previous volume's capstone established, in the frail elderly dialysis may add little survival while exacting a heavy toll in burden and hospital time, and conservative kidney management can offer comparable quality of life with a death in the preferred place. This decision belongs to the patient and is developed fully in the conservative-management and shared-decision chapters that follow; here it is enough to recognise that, in the frail, conservative care is a legitimate and often wise choice, not a default to dialysis. The chapter's shared-decision scripts cover the intensity and goals conversations that lead toward it.
Where judgement governs, and what stays firm
Much of this chapter is judgement rather than evidence, because the frail were excluded from the trials that define CKD care — the same evidence gap that troubled the cardiovascular chapter. So the targets, the pace of deprescribing, and the intensity of the pillars are individualised against frailty, prognosis, and values rather than dictated by a guideline number. What stays firm is the framework: distinguish the ageing kidney from progressive disease, weigh time-to-benefit against life expectancy, relax targets as frailty increases, deprescribe what no longer serves, preserve the effective baseline care, and share the values-driven decisions. The honest summary is that good CKD care in the frail is not a smaller version of standard care but a different, individualised exercise in matching intensity to the person — and that less, applied thoughtfully, is frequently more.
